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Introduction
The National Birth Defects Prevention Network (NBDPN) published the first Congenital 
Malformations Surveillance Report in 1997 and has annually released a report since 2000 
that contains state-specific population-based data on major birth defects and a directory 
describing data collection information for population-based birth defects surveillance 
programs in the United States. The birth defects in these reports have included conditions 
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affecting major organs of the central nervous, eye, ear, cardiovascular, orofacial, 
gastrointestinal, genitourinary, and musculoskeletal systems, as well as other disorders, 
including trisomies and amniotic band sequence.
In 2014, the NBDPN released an updated list of major birth defects as part of its national 
standards development for birth defects surveillance. The criteria used to guide deliberations 
for inclusion on the reportable list were: (1) public health importance; (2) accuracy of 
diagnosis; (3) amenable to prevention/intervention; (4) state of knowledge; (5) structural 
malformations, diagnosed within the first year of life; and (6) ability to separate into 
syndromic/nonsyndromic. For example, the NBDPN list now includes all 12 critical 
congenital heart defects (CCHDs) that are primary and secondary targets of pulse oximetry 
screening as a result of the addition of CCHD to the U.S. Recommended Universal 
Screening Panel for newborns (Mahle et al., 2012). Other noncardiac conditions that were 
added include clubfoot, cloacal exstrophy, craniosynostosis, deletion 22q11.2, 
holoprosencephaly, small intestinal atresia/stenosis, and Turner syndrome. These additions 
were balanced with the removal of several conditions, including: amniotic bands, aniridia, 
congenital hip dislocation, epispadias, fetus or newborn affected by maternal alcohol use, 
Hirschsprung disease (congenital megacolon), hydrocephalus, microcephalus, patent ductus 
arterious, and pyloric stenosis. Additional modifications to the list resulted in the regrouping 
of some conditions. Upper and lower limb deficiencies were collapsed into all limb 
deficiencies, while cleft lip with or without cleft palate was separated into cleft lip alone and 
cleft lip with cleft palate. Finally, obstructive genitourinary defect was limited to just the 
reporting of congenital posterior urethral valves. Table 1 presents the new reported list of 
birth defects and their diagnostic codes (International Classification of Diseases, 9th 
Revision, Clinical Modification [ICD-9-CM]; and Centers for Disease Control and 
Prevention/British Pediatric Association Classification of Diseases [CDC/BPA]).
The current report includes state-specific data from 39 population-based birth defects 
surveillance programs for the updated list of 47 major birth defects, and an accompanying 
directory describes program data collection status and contacts for state birth defects 
surveillance activities. In addition, the report highlights orofacial clefts (OFCs) from 29 state 
programs.
State-specific Data Collection and Presentation of 47 major birth defects
DATA COLLECTION
The NBDPN Data Committee, in collaboration with CDC, issued a call for data to 
population-based birth defects surveillance programs in April 2014. State programs were 
provided with a data dictionary and data table creation tools in Excel and SAS. CDC 
performed data quality checks, and state programs validated their data and approved final 
data table presentation.
Participating birth defects surveillance programs submitted case counts of the reportable 
birth defects shown in Table 1 and live births occurring from January 1, 2007 through 
December 31, 2011. These cases were stratified by U.S. Census maternal racial/ethnic 
groups: non-Hispanic white, non-Hispanic black, Hispanic, non-Hispanic Asian/Pacific 
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Islander, non-Hispanic American Indian/Alaska Native, and other/unknown. Additionally, 
trisomy conditions (trisomy 21 [Down syndrome], trisomy 13, and trisomy 18) were 
stratified by six maternal age categories: less than 20 years, 20 to 24 years, 25 to 29 years, 
30 to 34 years, 35 to 39 years, and 40+ years.
DATA PRESENTATION
State-specific data from 39 population-based birth defects surveillance programs for 2007 to 
2011 are included in the supplemental materials. The data are presented in two tables for 
each state. The first table shows defect counts and prevalence per 10,000 live births by 
maternal racial/ethnic categories, and the second table presents counts and prevalence for 
trisomies by two maternal age categories (less than 35 years, 35+ years). The prevalence is 
calculated by dividing the number of birth defect cases for any pregnancy outcome by the 
total number of live births for the reported years and then multiplying by 10,000 (Mason et 
al., 2005). The denominator used to calculate the prevalence for all birth defects is total live 
births except for hypospadias, which is calculated using total male live births.
Although the NBDPN provided a data dictionary and attempted to obtain the data in a 
uniform manner, variability can be expected in the reported birth defects data by state 
programs, given differences in coding systems used for case inclusion, case-finding 
methodology, and available data sources. State-specific notes and clarification about the 
data, such as methodological changes and probable/possible diagnoses, are included in the 
data tables. Additional information about each state program data collection methodology is 
available in the accompanying program directory.
Highlighting Orofacial Clefts
In addition to submitting data for the 47 NBDPN reportable birth defects, 29 state programs 
submitted supplemental data for this feature on orofacial clefts (OFCs). OFC are a 
phenotypically and etiologically diverse group of malformations that include cleft lip alone, 
cleft palate alone, and cleft lip with cleft palate, as well as several atypical cleft variations 
(Watkins et al., 2014). Orofacial clefts are among the most common major structural birth 
defects. In the United States, approximately 1 in 940 infants are born with cleft lip with or 
without cleft palate, and approximately 1 in 1574 infants are born with cleft palate (Parker et 
al., 2010).
Cleft lip alone and cleft lip with cleft palate both involve a bilateral, unilateral, or central 
defect of the upper lip that is visible in the newborn and often can be detected by prenatal 
ultrasound. In cleft lip alone, the defect can extend to the nasal floor, while in cleft lip with 
cleft palate, there also is a malformation of the upper gums (maxillary alveoli) or roof of the 
mouth (palate) that is often continuous with the separation of the lip. Cleft palate alone 
involves a hole or separation in the hard palate, soft palate, or the uvula (dangling structure 
at the rear of the soft palate), without a cleft lip.
Like other types of birth defects, OFCs are often classified by the presence or absence of 
other major malformations. Nonisolated clefts, which occur more commonly when the 
palate is involved (Genisca et al., 2009), are defined by the presence of at least one unrelated 
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defect of another organ system or body part that also has surgical, medical, or serious 
cosmetic consequences (Rasmussen et al., 2003). Without another major birth defect, OFCs 
are classified as isolated; a third classification category, syndromic, is used in birth defects 
studies when a single gene or chromosomal etiology has been identified for the cleft. 
However, this terminology has been applied inconsistently in the literature. Some 
researchers use the term nonsyndromic when referring to isolated clefts and syndromic to 
refer to nonisolated clefts, the latter sometimes being subdivided into syndromes of known 
cause, such as when a single gene disorder or chromosomal anomaly has been diagnosed, 
and syndromes of unknown cause (or idiopathic syndromic) when the specific etiology is 
undetermined (Watkins et al., 2014). It is important to note that accurate classification of 
birth defects often requires review by a clinical geneticist, and few birth defects surveillance 
programs routinely conduct such reviews on all birth defects, including OFCs. The data 
presented in this report include both isolated and nonisolated cases combined; therefore, 
caution should be used when comparing these data with other published reports that may be 
restricted to only isolated cases.
Children with OFCs typically require extensive multidisciplinary team care, especially 
during infancy and early childhood, and this care may continue throughout life (ACPA, 
2009). Their care includes feeding assistance, counseling, plastic/reconstructive surgery, 
orthodontics and dental care, otolaryngology, speech and audiology, psychosocial, and 
developmental follow-up. Depending on the cleft type, children may need different services, 
and the recommended timing of these services may differ (ACPA, 2009).
Due to the high prevalence of OFCs and health care use and costs associated with their 
treatment, improving the health of these children is an important public health goal. 
Disparities in prevalence, risk factors, health service use and access to care among children 
with OFCs recently were identified as public health research priorities by several convened 
expert groups sponsored by CDC (Yazdy et al., 2007). Evidence suggests that the three cleft 
phenotypes differ in etiology (especially for preventable risk factors), recurrence risk, 
treatment and management, and health service use (Harville et al., 2005; Cassell et al., 2008; 
ACPA, 2009; Boulet et al., 2009; Weiss et al., 2009).
DATA PRESENTATION OF OROFACIAL CLEFTS
Table 2 presents the counts and prevalence for OFCs from 2007 to 2011 by case-finding 
methodology and pregnancy outcome from 29 population-based birth defects surveillance 
programs in the United States. Data are also presented in Table 2 for each phenotype and 
combined total (cleft lip alone, cleft lip with cleft palate, and cleft palate alone) by maternal 
race/ethnicity, maternal age, and infant sex. A graphic display of the prevalence of OFCs by 
maternal race/ethnicity is shown in Figure 1 and by maternal age (years) in Figure 2. Table 3 
further stratifies the prevalence of OFCs by presenting a cross-tabulation of each OFC 
phenotype and combined total by maternal race/ethnicity and maternal age (years).
Infant sex-specific prevalence by maternal race/ethnicity and maternal age for each OFC 
phenotype is shown in Table 4. The 14 contributing states for Table 4 are a subset of the 29 
states included in Tables 2 and 3.
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Orofacial Cleft Discussion
OBSERVED PREVALENCE
The prevalence for cleft lip alone is 3.1 per 10,000 live births, 5.6 per 10,000 live births for 
cleft lip with cleft palate, and 5.9 per 10,000 live births for cleft palate alone. The overall 
unadjusted prevalence of all OFCs is 14.5, or approximately 1 in 690 births. Separating cleft 
lip with or without cleft palate into two categories results in approximately one-third of the 
cases as cleft lip alone and two-thirds as cleft lip with cleft palate. The prevalence of cleft lip 
with or without cleft palate is similar when compared with the data collected for the 2013 
NBDPN annual report (results not shown).
Worldwide, the prevalence of OFCs varies considerably. However, it is not clear to what 
extent differences in case ascertainment, case definition, and other surveillance methods 
versus true differences in population prevalence contribute to the geographic variability 
(IPDTOC, 2011; Mossey and Little, 2002). For example, the birth prevalence of cleft lip 
with or without cleft palate in Japan is 20.0 per 10,000 births—approximately twice the 
prevalence reported in the United States, Canada, and Australia (IPDTOC, 2011). 
Internationally, the birth prevalence of cleft palate shows even more striking geographic 
variation, with a 10- to 20-fold difference being reported, although it is likely that much of 
this variation is due to the difficulty in diagnosing some forms of cleft palate during the 
newborn period (Mossey and Modell, 2012).
RISK FACTORS
Orofacial clefts have a multifactorial etiology, involving a combination of both genetic and 
environmental risk factors, and complex gene-environment interaction, which are poorly 
understood. Several putative risk factors have been identified that tend to vary according to 
cleft phenotype. Many of these risk factors are preventable, notably maternal smoking 
(Little et al., 2004; Honein et al., 2007; US DHHS, 2014), alcohol consumption (Lorente et 
al., 2000; Romitti et al., 2007), diabetes and obesity (Cedergren and Kallen, 2005; Correa et 
al., 2008; Villamor et al., 2008), maternal diet (Munger, 2002), and certain medications 
(Hernandez-Diaz et al., 2000; Holmes et al., 2004; Werler et al., 2011; Margulis et al., 
2012). In this report, we examine prevalence of OFCs by maternal race/ethnicity, maternal 
age, and infant sex.
MATERNAL RACE/ETHNICITY
The overall estimated prevalence for OFCs for non-Hispanic whites was 15.4 per 10,000 
live births (Table 2). Compared with non-Hispanic whites, the prevalence was relatively 
similar for Hispanics (14.9 per 10,000 live births) and lower for other racial/ethnic groups 
except for non-Hispanic American Indians/Alaska Natives (20.5 per 10,000 live births). 
However, results should be interpreted with caution for the prevalence of OFCs for non-
Hispanic American Indians/Alaska Natives due to small numbers.
The variation differed when examining the prevalence by OFC phenotypes. Compared with 
non-Hispanic whites, the estimated prevalence of each OFC phenotype for non-Hispanic 
blacks remained significantly lower while for non-Hispanic Asians/Pacific Islanders, the 
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prevalence was slightly lower or not statistically significant. The prevalence of cleft lip with 
cleft palate was significantly higher for both Hispanics and non-Hispanic American Indians/
Alaska Natives compared with non-Hispanic whites while the observed prevalence for cleft 
lip alone and cleft palate alone among Hispanics was significantly lower but the increased 
prevalence among non-Hispanic American Indians/Alaska Natives was nonsignificant 
(Table 2 and Fig. 1).
Published studies showing OFCs by maternal race/ethnicity varied in several 
methodological aspects, including: (1) study population (for example: live births, live births 
and fetuses, inpatient admissions); (2) time periods; (3) geography; (4) case classification 
(for example: overall cleft cases, cleft lip with and without cleft palate, cleft lip alone, cleft 
palate alone, isolated cases); and (5) inclusion or exclusion of Hispanic ethnicity and the 
source of ethnicity information. Despite these differences, statistically significant 
observations for various case classifications consistently noted lower occurrence in non-
Hispanic blacks compared with non-Hispanic whites and Hispanics (Kirby et al., 2000; 
Genisca et al., 2009; Lebby et al., 2010). Several studies that have examined a broader range 
of maternal racial/ethnic groups reported similar findings, but also showed non-Hispanic 
American Indians/Alaska Natives with the highest occurrence of OFCs (Croen et al., 1998; 
Hashmi et al., 2005; Canfield et al., 2014). Consistent findings were seen with a lower 
prevalence of cleft palate alone among Hispanics compared with non-Hispanic whites; 
however, the prevalence for cleft lip alone varied depending on case classification. The 
studies reporting combined cleft lip with or without cleft palate showed no difference or a 
slight increase in the prevalence of OFCs among Hispanics compared with non-Hispanic 
whites. Genisca et al. (2009) presented estimated prevalences for the three OFC phenotypes 
by three maternal race/ethnicity categories (non-Hispanic white, non-Hispanic black, and 
Hispanic) and found a decreased prevalence among Hispanics for cleft lip alone and a 
nonsignificant but slightly higher prevalence for cleft lip with cleft palate. We had similar 
findings except the prevalence for cleft lip with cleft palate was significantly higher among 
Hispanics compared with non-Hispanic whites. A strength of our study was the ability to 
examine the three OFC phenotypes by the five maternal U.S. Census racial/ethnic groups.
MATERNAL AGE
We found that mothers who were greater than or equal to 35 years old had a higher 
prevalence of OFCs compared with those less than 35 years old. The prevalence for cleft lip 
alone and cleft lip with cleft palate was relatively stable across all maternal ages except that 
the prevalence was higher in mothers 40+ years old. For cleft palate alone, the prevalence 
increased with advanced maternal age, and the prevalence for mothers who were 40+ years 
old was approximately two-thirds higher than that of mothers less than 20 years old (Table 2 
and Fig. 2). This may be due, in part, to the higher rate of certain chromosomal birth defects 
among older women, such as trisomy 18 and trisomy 13, which are often associated with 
cleft palate.
Published studies showed inconsistent findings between maternal age and OFCs. Some 
reported an increase in prevalence with advanced maternal age, while others reported no 
evidence of an association (Vieira et al., 2002; Bille et al., 2005). One study using data from 
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a surveillance program found a statistically significant increase of isolated cleft lip with or 
without cleft palate among infants of mothers less than 20 years old but this was not 
observed for nonisolated cleft lip (DeRoo et al., 2003).
In general, our data showed the observed crude prevalence of OFCs was higher among 
mothers age 35 years and older within each racial/ethnic category with some exceptions 
(Table 3). For cleft lip with cleft palate among non-Hispanic whites and for cleft lip alone 
among non-Hispanic whites and non-Hispanic blacks, the prevalence was relatively similar 
between the maternal age categories.
INFANT SEX
The data in Table 2 indicated a higher prevalence of cleft lip alone, cleft lip with cleft palate, 
and overall for OFCs among males compared with females, but the prevalence was lower for 
cleft palate alone. Previous literature supports our results (Shaw et al., 1991; Forrester and 
Merz, 2004; Genisca et al., 2009; Messer et al., 2010;).
Table 4 presents the sex-specific prevalence of OFCs by maternal race/ethnicity and 
maternal age for 14 states, a subset of the 29 contributing states for this report. These 
findings are consistent with the previous literature that prevalence differs among the cleft 
phenotypes by infant sex and maternal race/ethnicity (Shaw et al., 1991; Croen et al., 1998; 
Kirby et al., 2000; Forrester and Merz, 2004; Hashmi et al., 2005; Genisca et al., 2009; 
Lebby et al., 2010; Messer et al., 2010; Canfield et al., 2014).
Conclusion
The 2014 NBDPN Congenital Malformations Surveillance Report, which includes data from 
39 population-based surveillance programs, continues to provide unique and important 
information to aid in the understanding of the occurrence and public health importance of 
birth defects in the United States. The focus on OFCs in the present report, using pooled 
surveillance data from 29 states, is intended to provide more detailed information on the 
occurrence of these serious birth defects. We hope the current population-based prevalence 
estimates of cleft lip alone, cleft lip with cleft palate, and cleft palate alone by maternal race/
ethnicity, maternal age, and infant sex in the United States will provide those using this 
report with the in-depth data they seek. This information can also guide clinicians, scientists, 
and public health officials concerned with treatment, management, and service planning for 
children with orofacial clefts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Prevalence of orofacial clefts by maternal race/ethnicity, 29 U.S. states, 2007 to 2011.
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FIGURE 2. 
Prevalence of orofacial clefts by maternal age (years), 29 U.S. states, 2007 to 2011.
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TABLE 1
Disease Classification Codes for Major Birth Defects Included in the 2014 NBDPN Annual Report
Birth defects ICD-9-CM codes CDC/BPA codes
Central nervous system
Anencephaly 740.0 – 740.1 740.00 – 740.10
Spina bifida without anencephaly 741.0, 741.9 w/o 740.0 – 
740.1
741.00 – 741.99 w/o 740.00 – 740.10
Encephalocele 742.0 742.00 – 742.09
Holoprosencephaly 742.2 742.26
Eye
Anophthalmia/microphthalmia 743.0, 743.1 743.00 – 743.10
Congenital cataract 743.30 – 743.34 743.32
Ear
Anotia/microtia 744.01, 744.23 744.01, 744.21
Cardiovascular
Common truncus (truncus arteriosus) 745.0 745.00 (excluding 745.01)
Transposition of the great arteries (TGA) 745.10, .12, .19 745.10 – 745.12, 745.18 – 745.19
dextro-Transposition of great arteries (d-TGA) – for CCHD 
screeninga
745.10 745.10, 745.11,745.19
Tetralogy of Fallot 745.2 745.20 – 745.21, 747.31
Ventricular septal defect 745.4 745.40 – 745.49 (excluding 745.487, 745.498)
Atrial septal defect 745.5 745.51 – 745.59
Atrioventricular septal defect (endocardial cushion defect) 745.60, .61, .69 745.60 – 745.69, 745.487
Pulmonary valve atresia and stenosis 746.01, 746.02 746.00, 746.01
Pulmonary valve atresia – for CCHD screeninga 746.01 746.00
Tricuspid valve atresia and stenosis 746.1 746.100, 746.106 (excluding 746.105)
Tricuspid valve atresia– for CCHD screeninga 746.1 746.100
Ebstein anomaly 746.2 746.20
Aortic valve stenosis 746.3 746.30
Hypoplastic left heart syndrome 746.7 746.70
Coarctation of aorta 747.10 747.10 – 747.19
Total anomalous pulmonary venous connection 747.41 747.42
Single ventricle 745.3 745.3
Interrupted aortic arch 747.11 747.215 – 747.217
Double outlet right ventricle 745.11 745.13 – 745.15
Orofacial
Cleft palate alone (without cleft lip) 749.0 749.00 – 749.09
Cleft lip alone (without cleft palate) 749.1 749.10 – 749.19
Cleft lip with cleft palate 749.20–749.25 749.20 – 749.29
Choanal atresia 748.0 748.00
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Birth defects ICD-9-CM codes CDC/BPA codes
Gastrointestinal
Esophageal atresia/tracheoesophageal fistula 750.3 750.30 – 750.35
Rectal and large intestinal atresia/stenosis 751.2 751.20 – 751.24
Biliary atresia 751.61 751.65
Small intestinal atresia/stenosis 751.1 751.10 – 751.19
Genitourinary
Renal agenesis/hypoplasia 753.0 753.00 – 753.01
Bladder exstrophy 753.5 753.50
Hypospadias 752.61 752.60 – 752.62(excluding 752.61 and 
752.621)
Congenital posterior urethral valves 753.6 753.60
Cloacal exstrophy 751.5 751.555
Musculoskeletal
Gastroschisis 756.73 (as of 10/1/09) 756.71
Omphalocele 756.72 (as of 10/1/09) 756.70
Diaphragmatic hernia 756.6 756.610 – 756.617
Limb deficiencies (reduction defects) 755.2 – 755.4 755.20 – 755.49
Craniosynostosis No specific code 756.00 – 756.03
Clubfoot 754.51, 754.70 754.50, 754.73(excluding 754.735)
Chromosomal
Trisomy 13 758.1 758.10 – 758.19
Trisomy 21 (Down syndrome) 758.0 758.00 – 758.09
Trisomy 18 758.2 758.20 – 758.29
Turner syndrome 758.6 758.60 – 758.69
Deletion 22q11.2 758.32 758.37
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; CDC/BPA, Centers for Disease Control and Prevention/
British Pediatric Association Classification of Diseases; NBDPN, National Birth Defects Prevention Network; w/o, without; CCHD, critical 
congenital heart defect.
a
The primary targets for CCHD screening include 7 conditions: hypoplastic left heart syndrome, pulmonary atresia with intact septum, tetralogy of 
Fallot, total anomalous pulmonary venous connection, dextro-transposition of great arteries (d-TGA), tricuspid atresia, and truncus arteriosus. The 
NBDPN traditionally monitors all TGA, and both atresia and stenosis for pulmonary and tricuspid valve conditions; however, for CCHD screening 
reporting purpose, these conditions are also reported as d-TGA, pulmonary valve atresia, and tricuspid valve atresia.
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